STYLE SHEET
GLOBAL CSS
COLORS
ANIMATIONS
MEDIA QUERY
SPACING SYSTEM

Why only for healthcare professionals?

The content on these information pages is directed solely at you if you are a doctor, nurse, or pharmacist, as it concerns treatment with prescription medicines.

Please confirm that you are a healthcare professional (healthcare assistant, nurse, doctor, psychologist, or other licensed healthcare professional).

Back to main page

Confirm and continue

News
August 22, 2025

OK: Gemma Collins' weight loss transformation with Yazen

Reality star Gemma Collins reveals her dramatic two dress size drop, crediting Yazen’s weight loss programme and personalised support for transforming her health and happiness.

Gemma Collins reveals weight loss transformation with Yazen

Gemma Collins has kicked off the new year with a dramatic body transformation, dropping two dress sizes and crediting Yazen’s weight loss programme for the change. The reality star shared her excitement on Instagram, revealing that working with Yazen’s digital healthcare team has helped her manage her weight responsibly.

“This has absolutely changed my life,” Gemma said, encouraging her fans to take control of their own health journeys with professional guidance.

Read the full article at OK magazine.

More news

WOD26: Data Reveals Persistent Shame & Stigma Around Obesity Treatment

Ahead of World Obesity Day on 4 March, Yazen is sharing new findings from internal patient data, revealing that shame and stigma remain major barriers to obesity care — even as effective medical treatments become more widely available.

UK firms eye GLP-1 benefits to cut sick leave and boost performance.

UK employers are increasingly considering weight-loss support as part of employee benefits, as new Yazen patient data links GLP-1 treatment to reduced sick days and improved workplace performance.

Yazen achieved record-breaking growth in 2025, doubling its revenue.

In 2025, Yazen's revenue surged 87% to nearly €29.4 million, with gross profits doubling to €16.5 million. Now treating over 37,000 active patients across seven countries, the company is eyeing further expansion into two more markets in 2026. Despite an EBITDA of –€5.7 million due to heavy growth investment, Yazen remains a leader in European obesity care.